Global Pharmacy: India’s Pharma Exports Surge 9.4% as Nation Eyes $130 Billion Milestone by 2030

Spread the Message

Read Time:4 Minute, 46 Second

NEW DELHI — In a significant boost to its reputation as the “pharmacy of the world,” India’s pharmaceutical sector has recorded a robust 9.4% growth in exports, reaching a valuation of $30.47 billion for the 2024–25 fiscal year. The Ministry of Commerce and Industry announced these figures on Saturday, outlining a strategic roadmap to achieve double-digit expansion by 2026–27.

The announcement, made during a high-level industry interaction titled “Scaling up Pharma Exports,” signals a pivotal shift in India’s manufacturing trajectory. With a current sectoral value of $60 billion, the government and industry leaders are now aligning resources to more than double that figure to $130 billion by the end of the decade.

A Global Pillar of Public Health

India currently ranks third globally in the volume of medicines produced, supplying essential medications to more than 200 countries. Perhaps most significant for global health security is the destination of these exports: over 60% are shipped to highly regulated markets with rigorous safety standards.

The United States remains the primary partner, accounting for 34% of India’s pharmaceutical exports, followed by Europe at 19%.

“This growth isn’t just about the balance sheet; it’s about global health equity,” says Dr. Aristha Sen, a global health policy consultant not involved in the government report. “When India scales its exports, it often means that life-saving generic medications become more accessible to lower-income populations in both developing and developed nations.”

From Generics to Biologics: The “Biopharma SHAKTI” Shift

While India has long been a powerhouse in “small molecule” generics—the traditional chemical pills most consumers are familiar with—the next phase of growth targets the frontier of modern medicine: biologics and biosimilars.

Biologics are complex medicines derived from living organisms, used to treat chronic conditions like cancer, rheumatoid arthritis, and diabetes. Because they are more difficult to manufacture than traditional drugs, they are often prohibitively expensive.

A cornerstone of the 2026–27 vision is the Biopharma SHAKTI initiative. With a proposed outlay of ₹10,000 crore (approximately $1.2 billion) over five years, the program aims to:

Strengthen the domestic ecosystem for biologic manufacturing.
Reduce dependence on imported raw materials (Active Pharmaceutical Ingredients).
Capture 5% of the total global biopharmaceutical market.

Understanding the Terms: Biologics vs. Generics

Feature	Traditional Generics	Biologics / Biosimilars
Source	Chemically synthesized	Derived from living cells/organisms
Complexity	Simple, stable structure	Large, complex, sensitive molecules
Manufacturing	High-volume, predictable	High-tech, specialized equipment
Example	Aspirin, Metformin	Insulin, Monoclonal antibodies

Supporting the Backbone: MSMEs and Regulatory Reform

The Ministry of Commerce highlighted that the surge to a $130 billion valuation requires more than just the success of “Big Pharma.” Micro, Small, and Medium Enterprises (MSMEs) are the backbone of the Indian industry but often struggle with the stringent documentation and inspection requirements of international regulators like the U.S. FDA.

The Commerce Secretary emphasized a “timely response” mechanism to help these smaller manufacturers navigate regulatory hurdles. By simplifying processes and aligning local policies with global standards, the government hopes to ensure that quality remains high even as volume increases.

“The challenge for India has always been maintaining a uniform gold standard of quality across thousands of manufacturing units,” notes Rajiv Nath, a medical devices industry expert. “The focus on ‘closer coordination’ between the CDSCO (India’s regulator) and international bodies is a necessary step to maintain the ‘trusted partner’ status mentioned by the Prime Minister.”

Public Health Implications and Challenges

For the average consumer, India’s expansion into the global pharma market has two primary implications:

Affordability: Increased competition in the biosimilar market can significantly drive down the cost of expensive treatments for cancer and autoimmune diseases.
Supply Chain Resilience: By reducing import dependence for raw materials, India aims to prevent the drug shortages that plagued the global market during the early 2020s.

However, some experts urge caution. Critics of rapid expansion point out that aggressive growth must be matched by equally aggressive oversight.

“Double-digit growth is an ambitious target,” says Sarah Jenkins, an international trade analyst. “To achieve this while navigating the evolving patent laws in the West and maintaining rigorous quality control will require unprecedented transparency from Indian manufacturers.”

The Road to 2030

The Union Budget 2026–27 has placed biopharma at the center of India’s manufacturing priorities. As the industry moves toward its $130 billion goal, the focus will likely remain on digital transformation in manufacturing and the adoption of “Green Chemistry” to reduce the environmental footprint of large-scale drug production.

With the backing of the Directorate General of Foreign Trade (DGFT) and the Central Drugs Standard Control Organisation (CDSCO), the Indian pharmaceutical industry is no longer just looking to be a provider of cheap alternatives, but a leader in medical innovation.

How This Affects You

Cost Savings: As India increases its share of the biosimilar market, patients worldwide may see a reduction in out-of-pocket costs for complex specialty drugs.
Quality Assurance: Increased government oversight and alignment with US/EU standards mean that “Made in India” labels are increasingly synonymous with high-tier global safety standards.
Drug Availability: A more robust Indian export market helps ensure a steady global supply of chronic disease medications, reducing the risk of “pharmacy shelf” shortages.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.